Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed aggressive non-Hodgkin's lymphoma including:~  * Peripheral T-cell lymphoma not otherwise specified~ * Anaplastic large null-/T-cell lymphoma~ * Diffuse large B-cell lymphoma including:~    * Primary mediastinal large B-cell lymphoma with sclerosis~   * Intravascular large B-cell lymphoma~   * Immunoblastic B-cell lymphoma~   * T-cell-rich B-cell lymphoma~   * Anaplastic large B-cell lymphoma~* At least one bidimensionally measurable lesion with clearly defined margins at least 2 cm in the largest dimension by physical examination or CT scan~* No prior or active CNS lymphoma or AIDS-related lymphoma~* Must have received 2 or more prior chemotherapy courses from time of diagnosis of aggressive lymphoma or from time of biopsy-proven transformation from indolent to aggressive~  * Prior first and second-line therapy must have been combination chemotherapy~ * Prior first-line chemotherapy regimen must have contained anthracycline~ * Must have had at least a minor response to first-line therapy~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-3~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count at least 500/mm\^3 (unless due to lymphoma bone marrow involvement)~* Platelet count at least 50,000/mm\^3 (unless due to lymphoma bone marrow involvement)~Hepatic:~* Bilirubin no greater than 2 times upper limit of normal (ULN)~* ALT no greater than 4 times ULN~* Alkaline phosphatase no greater than 4 times ULN~Renal:~* Not specified~Neurologic:~* No prior neurological disorders unrelated to chemotherapy (including familial neurological diseases or acquired demyelinating disorders)~* No neuromuscular impairment (neuromotor, neurosensory, or neurocerebellar)~* No prior grade 3 or 4 sensory or motor neuropathy related to chemotherapy~Other:~* No uncontrolled severe medical illness or infection~* HIV negative~* No other malignancies within the past 5 years except curatively resected basal cell skin cancer or carcinoma in situ of the cervix~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Radiotherapy~* No prior allogeneic bone marrow or peripheral blood stem cell transplantation~* At least 4 weeks since prior immunotherapy~* No concurrent biological agents~Chemotherapy:~* See Disease Characteristics~* At least 4 weeks since prior chemotherapy~Endocrine therapy:~* At least 4 weeks since prior corticosteroids at a dose greater than 10 mg/day of prednisone or equivalent~Radiotherapy:~* Prior involved-field radiotherapy allowed if irradiated area is not the only source of measurable disease~* Prior total body radiotherapy with high-dose therapy and autologous stem cell transplantation allowed~* At least 4 weeks since prior radiotherapy~* No concurrent radiotherapy to any disease site~Surgery:~* At least 4 weeks since prior major surgery except for diagnosis of lymphoma~* No concurrent surgical removal of any indicator lesion~Other:~* At least 4 weeks since prior alternative or investigational anticancer treatment~* No other concurrent systemic anticancer therapy~* No other concurrent investigational drug~* No concurrent phenytoin~* No concurrent hepatic drug metabolism inhibitors or inducers (cytochrome P450 isoenzymes in the CYP 3A subfamily)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete